Keyphrases
Prospective Phase II Study
100%
Modified Citrus Pectin
100%
Non-metastatic Biochemically Relapsed Prostate Cancer
100%
Pectasol
83%
Treatment Phase
50%
Second-line Treatment
33%
Prostate-specific Antigen Doubling Time
33%
Out-of-pocket
16%
In Cancer
16%
Long-term Response
16%
Disease Progression
16%
Long-term Treatment
16%
Toxic Chemicals
16%
Competitive Inhibitor
16%
Food Supplements
16%
Cancer Pathogenesis
16%
Local Therapy
16%
Galectin-3 (Gal-3)
16%
Phase II Study
16%
Optimal Therapy
16%
Generally Recognized as Safe
16%
Medicine and Dentistry
Prostate Cancer
100%
Pectin
100%
Prostate Specific Antigen
33%
Malignant Neoplasm
16%
Toxic Substance
16%
Disease Exacerbation
16%
Competitive Inhibition
16%
Food Supplement
16%
Local Therapy
16%
Galectin 3
16%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Pectin
100%
Prostate Specific Antigen
33%
Malignant Neoplasm
16%
Disease Exacerbation
16%
Toxic Substance
16%
Competitive Inhibitor
16%
Galectin 3
16%
Biochemistry, Genetics and Molecular Biology
Citrus
100%
Pectin
100%
Prostate-Specific Antigen
33%
Competitive Inhibition
16%
Galectin-3
16%
Immunology and Microbiology
Citrus
100%
Prostate Specific Antigen
33%
Competitive Inhibition
16%
Galectin 3
16%